Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an update.
Hemogenyx Pharmaceuticals has announced the posting of its Annual Report and Accounts for the year ending 31 December 2024, along with the Notice of the Annual General Meeting (AGM) scheduled for 29 May 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its operations and positioning in the biopharmaceutical industry.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded biopharmaceutical company based in London, with subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, aiming to expand the use of bone marrow transplantation for patients with life-threatening conditions. They are working on various product candidates and platform technologies to drive novel product development.
YTD Price Performance: -55.56%
Average Trading Volume: 36,618
Technical Sentiment Signal: Buy
Current Market Cap: £7.37M
For detailed information about HEMO stock, go to TipRanks’ Stock Analysis page.